Patents by Inventor Sharon D. Wilhelm

Sharon D. Wilhelm has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • POTENT CONJUGATES AND HYDROPHILIC LINKERS
    Publication number: 20160114052
    Abstract: Linkers for binding drugs to cell binding agents are modified to hydrophilic linkers by incorporating a polyethylene glycol spacer. The potency or the efficacy of the cell-binding agent-drug conjugates is surprisingly enhanced several folds in a variety of cancer cell types, including those expressing a low number of antigens on the cell surface or cancer cells that are resistant to treatment. A method for preparing maytansinoids bearing a thioether moiety and a reactive group which allows the maytansinoid to be linked to a cell-binding agent in essentially a single step is also provided.
    Type: Application
    Filed: August 25, 2015
    Publication date: April 28, 2016
    Applicant: IMMUNOGEN, INC.
    Inventors: Rajeeva Singh, Yelena Kovtun, Sharon D. Wilhelm, Ravi V.J. Chari
  • CYTOTOXIC AGENTS COMPRISING NEW ANSAMITOCIN DERIVATIVES
    Publication number: 20160058882
    Abstract: New ansamitocin derivatives bearing a linking group are disclosed. Also disclosed are methods for the synthesis of these new ansamitocin derivatives and methods for their linkage to cell-binding agents. The ansamitocin derivative-cell-binding agent conjugates are useful as therapeutic agents, which are delivered specifically to target cells and are cytotoxic. These conjugates display vastly improved therapeutic efficacy in animal tumor models compared to the previously described agents.
    Type: Application
    Filed: May 22, 2015
    Publication date: March 3, 2016
    Inventors: Ravi V.J. Chari, Wayne C. Widdison, Sharon D. Wilhelm
  • Potent conjugates and hydrophilic linkers
    Patent number: 9150649
    Abstract: Linkers for binding drugs to cell binding agents are modified to hydrophilic linkers by incorporating a polyethylene glycol spacer. The potency or the efficacy of the cell-binding agent-drug conjugates is surprisingly enhanced several folds in a variety of cancer cell types, including those expressing a low number of antigens on the cell surface or cancer cells that are resistant to treatment. A method for preparing maytansinoids bearing a thioether moiety and a reactive group which allows the maytansinoid to be linked to a cell-binding agent in essentially a single step is also provided.
    Type: Grant
    Filed: October 6, 2009
    Date of Patent: October 6, 2015
    Assignee: ImmunoGen, Inc.
    Inventors: Rajeeva Singh, Yelena Kovtun, Sharon D. Wilhelm, Ravi V. J. Chari
  • Cytotoxic agents comprising new ansamitocin derivatives
    Patent number: 9090629
    Abstract: New ansamitocin derivatives bearing a linking group are disclosed. Also disclosed are methods for the synthesis of these new ansamitocin derivatives and methods for their linkage to cell-binding agents. The ansamitocin derivative-cell-binding agent conjugates are useful as therapeutic agents, which are delivered specifically to target cells and are cytotoxic. These conjugates display vastly improved therapeutic efficacy in animal tumor models compared to the previously described agents.
    Type: Grant
    Filed: November 3, 2011
    Date of Patent: July 28, 2015
    Assignee: ImmunoGen, Inc.
    Inventors: Ravi V. J. Chari, Wayne C. Widdison, Sharon D. Wilhelm
  • CYTOTOXIC AGENTS COMPRISING NEW ANSAMITOCIN DERIVATIVES
    Publication number: 20130323268
    Abstract: New ansamitocin derivatives bearing a linking group are disclosed. Also disclosed are methods for the synthesis of these new ansamitocin derivatives and methods for their linkage to cell-binding agents. The ansamitocin derivative-cell-binding agent conjugates are useful as therapeutic agents, which are delivered specifically to target cells and are cytotoxic. These conjugates display vastly improved therapeutic efficacy in animal tumor models compared to the previously described agents.
    Type: Application
    Filed: November 3, 2011
    Publication date: December 5, 2013
    Applicant: IMMUNOGEN, INC.
    Inventors: Ravi V.J. Chari, Wayne C. Widdison, Sharon D. Wilhelm
  • POTENT CONJUGATES AND HYDROPHILIC LINKERS
    Publication number: 20120226026
    Abstract: Linkers for binding drugs to cell binding agents are modified to hydrophilic linkers by incorporating a polyethylene glycol spacer. The potency or the efficacy of the cell-binding agent-drug conjugates is surprisingly enhanced several folds in a variety of cancer cell types, including those expressing a low number of antigens on the cell surface or cancer cells that are resistant to treatment. A method for preparing maytansinoids bearing a thioether moiety and a reactive group which allows the maytansinoid to be linked to a cell-binding agent in essentially a single step is also provided.
    Type: Application
    Filed: May 17, 2012
    Publication date: September 6, 2012
    Applicant: IMMUNOGEN, INC.
    Inventors: Rajeeva SINGH, Sharon D. WILHELM, Ravi V.J. CHARI
  • POTENT CONJUGATES AND HYDROPHILIC LINKERS
    Publication number: 20100129314
    Abstract: Linkers for binding drugs to cell binding agents are modified to hydrophilic linkers by incorporating a polyethylene glycol spacer. The potency or the efficacy of the cell-binding agent-drug conjugates is surprisingly enhanced several folds in a variety of cancer cell types, including those expressing a low number of antigens on the cell surface or cancer cells that are resistant to treatment. A method for preparing maytansinoids bearing a thioether moiety and a reactive group which allows the maytansinoid to be linked to a cell-binding agent in essentially a single step is also provided.
    Type: Application
    Filed: October 6, 2009
    Publication date: May 27, 2010
    Applicant: Immunogen Inc.
    Inventors: Rajeeva Singh, Yelena Kovtun, Sharon D. Wilhelm, Ravi V.J. Chari